---
title: "FDA Grants Accelerated Approval to Tudriqev for Anti-PD-1 Refractory Advanced Melanoma"
id: "fda-news-releases-0-fda-approves-new-engineered-viral-immunotherapy-for-patients-with-treatment"
canonical_url: "https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-approves-new-engineered-viral-immunotherapy-for-patients-with-treatment"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "FDA News Releases"
source_url: "http://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma"
published_at: "2026-08-06T19:56:59.000Z"
evidence_level: "Agency Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA Grants Accelerated Approval to Tudriqev for Anti-PD-1 Refractory Advanced Melanoma
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-approves-new-engineered-viral-immunotherapy-for-patients-with-treatment
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** FDA News Releases
- **Source URL:** [Original Journal Publication](http://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma)
- **Published At:** 2026-08-06T19:56:59.000Z
- **Evidence Rating:** Agency Feed
## Executive GIST (TL;DR)
- The FDA granted accelerated approval to **Tudriqev (vusolimogene oderparepvec-wtpg)** for adult patients with unresectable advanced cutaneous melanoma who progressed on prior **PD-1–blocking** therapy, in combination with **nivolumab**. - Approval announced August 6, 2026, for use in patients with treatment-resistant advanced melanoma after PD-1 inhibitor progression. - Tudriqev is an **oncolytic viral therapy** derived from genetically modified herpes simplex virus type 1 (HSV-1) that replicates in and lyses tumor cells and can stimulate an anti-tumor immune response. - Treatment regimen: intratumoral injections every two weeks for eight consecutive doses (lower concentration first dose, higher for subsequent doses); nivolumab IV begins at week three. - Pivotal single-arm, open-label, multiregional trial enrolled 140 patients; 91 were evaluated for response. Objective response rate (ORR) was 24%, and median duration of response was 14.1 months. - Common adverse reactions (>10%) included fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reactions, headache, cough, influenza-like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. - Key safety concerns and warnings: risk of viral transmission to close contacts, possible herpes infection or reactivation in patients, and procedure-related injection complications. - The application had Breakthrough Therapy and Priority Review designations; the FDA convened the Cellular, Tissue, and Gene Therapies Advisory Committee on July 30, 2026, which included public input from patients, advocates, clinicians and experts. - Approval was granted to Replimune, Inc., under the accelerated approval pathway based on ORR and duration of response; confirmatory post-approval trials are required to verify clinical benefit for continued approval. - FDA senior officials emphasized the unmet need in anti-PD-1 refractory melanoma and characterized the approval as providing a meaningful new treatment option for this population.
## Clinical Analysis & Structured Key Points
* [Skip to main content](https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma#main-content) * [Skip to FDA Search](https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma#search-form) * [Skip to in this section menu](https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma#section-nav) * [Skip to footer links](https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma#footer) ![U.S. flag](https://www.fda.gov/themes/custom/preview/assets/images/US_Flag.png) An official website of the United States government [Here’s how you know ](https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma) ![Dot gov](https://www.fda.gov/themes/custom/preview/assets/images/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. ![SSL](https://www.fda.gov/themes/custom/preview/assets/images/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. ###### Recall Alert An update on the Cyclospora outbreak available [here](https://www.fda.gov/food/outbreaks-foodborne-illness/investigation-5-state-outbreak-cyclospora-illnesses-iceberg-lettuce-july-2026). [ ![U.S. Food and Drug Administration logo](https://www.fda.gov/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg) ](https://www.fda.gov/ "FDA Homepage") * Search * Menu Search FDA Submit search ## Featured * [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=referral&utm_source=fda_gov_menu "Report a Problem with an FDA Regulated Product") * [Contact FDA](https://www.fda.gov/about-fda/contact-fda) * [FDA Guidance Documents](https://www.fda.gov/regulatory-information/search-fda-guidance-documents) * [Recalls, Market Withdrawals and Safety Alerts](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts) * [Press Announcements](https://www.fda.gov/news-events/newsroom/press-announcements) * [Warning Letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) * [Advisory Committees](https://www.fda.gov/advisory-committees) * [En Español](https://www.fda.gov/fda-en-espanol) ## Products * [Food](https://www.fda.gov/food) * [Drugs](https://www.fda.gov/drugs) * [Medical Devices](https://www.fda.gov/medical-devices) * [Radiation-Emitting Products](https://www.fda.gov/radiation-emitting-products) * [Vaccines, Blood, and Biologics](https://www.fda.gov/vaccines-blood-biologics) * [Animal and Veterinary](https://www.fda.gov/animal-veterinary) * [Cosmetics](https://www.fda.gov/cosmetics) * [Tobacco Products](https://www.fda.gov/tobacco-products) ## Topics * [About FDA](https://www.fda.gov/about-fda) * [Combination Products](https://www.fda.gov/combination-products) * [Regulatory Information](https://www.fda.gov/regulatory-information) * [Safety](https://www.fda.gov/safety) * [Emergency Preparedness](https://www.fda.gov/emergency-preparedness-and-response) * [International Programs](https://www.fda.gov/international-programs) * [News and Events](https://www.fda.gov/news-events) * [Training and Continuing Education](https://www.fda.gov/training-and-continuing-education) * [Inspections and Compliance](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations) * [Science and Research](https://www.fda.gov/science-research) ## Information For * [Consumers](https://www.fda.gov/consumers) * [Patients](https://www.fda.gov/patients) * [Industry](https://www.fda.gov/industry) * [Health Professionals](https://www.fda.gov/health-professionals) * [Federal, State and Local Officials](https://www.fda.gov/federal-state-local-tribal-and-territorial-officials) 1. [Home](https://www.fda.gov/) 2. [News & Events](https://www.fda.gov/news-events) 3. [FDA Newsroom](https://www.fda.gov/news-events/fda-newsroom) 4. [Press Announcements](https://www.fda.gov/news-events/fda-newsroom/press-announcements) 5. FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma 1. [ Press Announcements ](https://www.fda.gov/news-events/fda-newsroom/press-announcements "Press Announcements") [In this section](https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma#section-nav) * [ Press Announcements ](https://www.fda.gov/news-events/fda-newsroom/press-announcements "Press Announcements") FDA News Release # FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma Approval Offers New Hope for Patients with Anti-PD-1 Refractory Melanoma [ More Press Announcements](https://www.fda.gov/news-events/newsroom/press-announcements) For Immediate Release: August 06, 2026 The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma. Tudriqev is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. The approval is supported by data from a clinical trial showing that one in four patients responded to treatment, with responses lasting a median of nearly 14 months, offering clinicians a meaningful new tool for a patient population. In reaching this decision, the FDA also considered input from clinical experts and patient advocates who emphasized the urgent need for effective options in this refractory population. “For patients with advanced melanoma that has stopped responding to PD-1 blocking therapy, the prognosis is often devastating, and options have been far too limited. Clinicians managing these patients know this urgency firsthand,” **said Karim Mikhail, B. Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research (CBER)**. “Today’s important milestone gives oncologists a meaningful new tool — and more patients a fighting chance.” Anti-PD-1 refractory melanoma is advanced skin cancer that no longer responds to a widely used class of immunotherapy drugs. Despite treatment, the cancer may continue to grow because of developed mechanisms to evade the immune system’s ability to detect and destroy it. Tudriqev is an oncolytic viral therapy based on a modified herpes simplex virus type 1 (HSV-1) that is engineered to selectively target and destroy cancer cells. Once inside a tumor, the virus replicates and breaks cancer cells apart, while simultaneously triggering the body’s immune system to recognize and attack the cancer. When used in combination with nivolumab, an anti-PD-1 immunotherapy, Tudriqev may help restore an anti-tumor immune response in patients whose cancer had previously stopped responding to immunotherapy. Tudriqev is injected directly into tumors once every two weeks for eight consecutive doses, with the dosage amount determined by the size of the tumor. A lower concentration is used for the first dose, followed by a higher concentration for all remaining doses. A second drug, nivolumab, is given intravenously beginning at week three of treatment. “For patients with advanced melanoma who have exhausted immunotherapy options, today’s approval offers a meaningful new path forward — grounded in early evidence and backed by the accountability that accelerated approval demands,” **said Megha Kaushal, M.D., MSc., Acting Deputy Director of the CBER Office of Therapeutic Products**. The safety and effectiveness of Tudriqev were evaluated in an open-label, multiregional, single-arm trial enrolling 140 adult patients with Stage IIIB, IIIC or IV unresectable advanced melanoma who experienced disease progression on at least eight consecutive weeks of prior anti-PD-1-based therapy. In the trial, 91 patients were evaluated and 24% of patients achieved an objective response. Responses had a median duration of 14.1 months. The most common adverse reactions reported in more than 10% of patients were fatigue, fever (pyrexia), infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza-like illness, rash, vomiting, itching (pruritus), arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. Important safety warnings include the risk of accidentally spreading a herpes infection to close contacts, the possibility of a herpes infection developing or reactivating in the patient, and complications related to injection procedure. On July 30, 2026, the FDA convened the [Cellular, Tissue, and Gene Therapies Advisory Committee Meeting](https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-july-30-2026-meeting-announcement-updated "Cellular, Tissue, and Gene Therapies Advisory Committee July 30, 2026 Meeting Announcement- UPDATED INFORMATION \(as of 7/16/2026\) - 07/30/2026") for this application. The meeting included a public hearing section to hear from patients, patient advocates, clinicians and independent experts and a session for discussion and deliberation among committee members. The application was granted [Breakthrough Therapy](https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy "Breakthrough Therapy") and [Priority Review](https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review "Priority Review") designations. FDA granted the approval of Tudriqev to Replimune, Inc. The approval is granted under the FDA’s accelerated approval pathway based on objective response rate and duration of response. As a condition of accelerated approval, Replimune, Inc., is required to conduct post-approval trial(s) to verify and describe the clinical benefit of Tudriqev. Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s). * * * **Media:** [FDA Request for Comment](https://www.hhs.gov/request-for-comment-form/index.html?Agency=FDA) 202-690-6343 **Consumer:** 888-INFO-FDA ### Boilerplate The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. * * * * ## Content current as of: 08/06/2026 * ## Regulated Product(s) * Biologics * ## Follow FDA * [ Follow @US_FDA on X ](https://x.com/US_FDA)[External Link Disclaimer](http://www.fda.gov/about-fda/website-policies/website-disclaimer) * [Follow FDA on Facebook](https://www.facebook.com/FDA)[External Link Disclaimer](http://www.fda.gov/about-fda/website-policies/website-disclaimer) * [ Follow @FDAMedia on X ](https://x.com/FDAMedia)[External Link Disclaimer](http://www.fda.gov/about-fda/website-policies/website-disclaimer) Feedback * [FDA Archive](https://www.fda.gov/about-fda/about-website/fdagov-archive) * [About FDA](https://www.fda.gov/about-fda) * [Accessibility](https://www.fda.gov/about-fda/about-website/internet-accessibility) * [Visitor Information](https://www.fda.gov/about-fda/visitor-information) * [Website Policies / Privacy](https://www.fda.gov/about-fda/about-website/website-policies) * [No FEAR Act](https://www.fda.gov/about-fda/jobs-and-training-fda/no-fear-act) * [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) * [FOIA](https://www.fda.gov/regulatory-information/freedom-information "Freedom of Information Act") * [HHS.gov](https://www.hhs.gov/ "Health and Human Services") * [USA.gov](https://www.usa.gov/) [Contact FDA](https://www.fda.gov/about-fda/contact-fda) [ Follow FDA on Facebook ](https://www.facebook.com/FDA "Follow FDA on Facebook") [ Follow FDA on X ](https://x.com/US_FDA "Follow FDA on X") [ Follow FDA on Instagram ](https://instagram.com/FDA "Follow FDA on Instagram") [ Follow FDA on LinkedIn ](https://www.linkedin.com/company/fda/ "Follow FDA on LinkedIn") [ View FDA videos on YouTube ](https://youtube.com/@US_FDA "View FDA videos on YouTube") [ Subscribe to FDA RSS feeds ](https://www.fda.gov/about-fda/contact-fda/subscribe-podcasts-and-news-feeds "Subscribe to FDA RSS feeds") [ ![Food and Drug Administration Logo](https://www.fda.gov/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg) ](https://www.fda.gov/ "FDA Homepage") Contact Number 1-888-INFO-FDA (1-888-463-6332) [Back to Top](https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma)
## Related Clinical Research

- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Challenging FDA-Approved Cancer Drug Dosages: A Patient and Research Perspective](https://medichelpline.com/clinical-feed/kff-health-news-2-how-much-of-a-cancer-drug-is-too-much-patients-researchers-challenge-fda.md)
- [Predicting Cancer Immunotherapy Response Using Dynamic CD8+ T Cell Changes — Pan‑Cancer Retrospect](https://medichelpline.com/clinical-feed/frontiers-in-immunology-13-a-predictive-model-for-immunotherapy-efficacy-in-cancer-based-on-dynamic.md)
- [Insufficiently reported: tumor-infiltrating immune cell predictors of recurrence in melanoma after](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-tumor-infiltrating-immune-cell-types-predicting-recurrence-free-survival-in.md)
- [Cost-effectiveness of pembrolizumab (neoadjuvant + adjuvant) for resectable LA HNSCC in Switzerland](https://medichelpline.com/clinical-feed/pubmed-42565346.md) (DOI: 10.1080/13696998.2026.2712763)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.